Evidence-Based Medicine
Copyright ©The Author(s) 2015.
World J Clin Cases. Nov 16, 2015; 3(11): 935-941
Published online Nov 16, 2015. doi: 10.12998/wjcc.v3.i11.935
Table 3 Similarities and differences between a patient-based and population based cost-effectiveness model
Patient-based cost-effectiveness modelPopulation-based cost-effectiveness model
Patient-related therapeutic and economic measures for clinical and economic evaluations
The relevant economic issues, as indicated for CDI like:
increasing incidence of CDI,
person-to person transmission of CDI,
development of vancomycin-resistant enterococci (VRE),
or other antibiotic induced resistant bacteria,
impact for department of microbiology diagnostic testing
isolation measures and
closing of wards of hospitals
other supra-patient effects
Limited health economic outcome in terms of time horizon and perspective
The patient-based cost-effectiveness model only captures the short-term time horizon of the CDI episode within the hospital setting at a patient level